Tradestie Institutional Equity Comparison Engine · Market Close Nov 16, 2026

PCVX vs LEGN: Which Stock Is the Better Buy Now?

Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.

LEGN Wins Head-to-Head Institutional Verdict (5–1 across 6 Pillars · 5–4 Matrix Metrics)

LEGN Overall Winner 6-Pillar Tally: PCVX 1 – 5 LEGN Matrix Metrics: PCVX 4 – 5 LEGN

As of Nov 16, 2026, Legend Biotech Corporation (LEGN) is the stronger overall head-to-head candidate over Vaxcyte, Inc. (PCVX) in the Tradestie Institutional Equity Comparison Engine, winning 5–4 core matrix metrics and 5–1 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Profitability & Quality). PCVX carries a Unified Composite Score of 47.3/100 (HOLD) at $62.02 (N/M Forward P/E, 0.0% operating margin), whereas LEGN carries 42.8/100 (HOLD) at $16.45 (27.5x Forward P/E, 2.8% operating margin).

  • Composite vs. Pillar Nuance: While PCVX currently prints a higher short-term Unified Composite Score (47.3/100 HOLD vs. LEGN 42.8/100 HOLD), LEGN captures the overall institutional head-to-head verdict (5–4 matrix metrics and 5–1 across the 6 pillars) due to superior fundamental profitability (2.8% vs. 0.0% operating margin) and revenue trajectory (+32.0% vs. +0.0% YoY).
  • Technical & Structure Timing Caution: PCVX trades in a Neutral technical trend (CONSOLIDATION options phase, RSI 47.2); meanwhile LEGN is in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 34.5). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

Executive Snapshot Side-by-Side Composite Ratings & Technical Regime

Ask Alpha AI About PCVX vs LEGN
PCVX NASDAQ
Vaxcyte, Inc. Common Stock
Biological Products, (No Disgnostic Substances)
$62.02
-2.13% 1D
Market Cap $10.2B
TTM Revenue N/A
Forward P/E N/M
Beta / 30D Vol 1.28β · 57% Vol
Unified Composite Score
47.3 / 100 HOLD
Tech 42.0 Fund 50.0 Flow 65.0 Mom 50.0
Weinstein Technical Phase Neutral · Hold
Mixed signals - no dominant trend phase, RSI 47
RSI-14: 47.2 · SMA20: $63.25 · SMA50: $62.25
LEGN NASDAQ Head-to-Head Winner
Legend Biotech Corporation American Depositary Shares
Pharmaceutical Preparations
$16.45
-6.03% 1D
Market Cap $3.6B
TTM Revenue $1.36B
Forward P/E 27.5x
Beta / 30D Vol 0.65β · 82% Vol
Unified Composite Score
42.8 / 100 HOLD
Tech 27.0 Fund 45.0 Flow 50.0 Mom 60.0
Weinstein Technical Phase Markdown · Sell / avoid
Price below a falling SMA50 (slope -1.0%), weak momentum, RSI 34
RSI-14: 34.5 · SMA20: $20.61 · SMA50: $19.47

6-Pillar Scorecard Institutional Category Breakdown (PCVX 1 – 5 LEGN)

Columns: Metric · PCVX · LEGN
1. Valuation Multiples LEGN
Forward P/E N/M 27.5x
Trailing P/E N/M 23.0x
PEG Ratio N/M N/M
EV / Revenue N/M 2.6x
2. Growth & Scale LEGN
Revenue Growth (YoY) +0.0% +32.0%
Earnings Growth (YoY) +0.0% +0.0%
TTM Revenue (USD) N/A $1.36B
Market Cap $10.2B $3.6B
3. Profitability & Quality LEGN
Gross Margin N/A 57.0%
Operating Margin 0.0% 2.8%
Net Profit Margin 0.0% -0.0%
Return on Equity (ROE) -42.7% -0.0%
4. Balance Sheet & Cash Flow LEGN
Cash Generation (TTM) -$995M $50M EBITDA
Cash Flow Margin N/A 3.7% EBITDA Mgn
Net Cash / Leverage $96M Net Debt (0.09x D/E) $6.56 Book/Sh · -0.0% ROE
Dividend Yield None (0.00%) None (0.00%)
5. Options & Positioning PCVX
Options Structure Phase CONSOLIDATION UNCLASSIFIED
Current IV / %ile 52.2% (10th %ile) 42.4% (24th %ile)
Put/Call OI Skew N/A Thin ADR Chain
OBV Trend / Tech Phase NEUTRAL · Neutral NEUTRAL · Markdown
6. R&D & Supply-Chain Moat LEGN
OpEx & R&D Intensity N/A 54.2% of Rev ($736M)
90D R&D Disclosures 0 papers 0 papers
Competitive Moat Cyclical / Execution-Driven Positioning Cyclical / Execution-Driven Positioning
Supply-Chain Role Biotechnology Operator Biotechnology Operator

Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table

Core Matrix Wins: PCVX (4) vs LEGN (5)
Institutional Metric PCVX LEGN Criterion Row Edge
Market Capitalization
Scale
$10.2B $3.6B Larger Scale PCVX
Trailing P/E Ratio
Valuation
N/M 23.0x Lower Multiple LEGN
Forward P/E Ratio
Valuation
N/M 27.5x Lower Multiple LEGN
Revenue Growth (YoY)
Growth
+0.0% +32.0% Higher Growth LEGN
Operating Margin (TTM)
Profitability
0.0% 2.8% Higher Margin LEGN
Net Profit Margin
Profitability
0.0% -0.0% Higher Margin Tie
Return on Equity (ROE)
Capital Efficiency
-42.7% -0.0% Higher ROE LEGN
52-Week Range Position
Momentum
41% ($42–$91) 1% ($16–$38) Stronger Trend PCVX
Beta / 30D Volatility
Risk Regime
1.28β · 57% Vol 0.65β · 82% Vol Lower Realized Risk PCVX
Unified Institutional Score
Composite Signal
47.3 / 100 (HOLD) 42.8 / 100 (HOLD) Higher Composite PCVX
Trailing 12M Revenue (USD)
Operating Scale
N/A $1.36B FX-Normalized USD Scale
Gross Profit Margin (TTM)
Unit Pricing Power
N/A 57.0% Higher Margin Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
N/M PEG · N/M EV/Rev N/M PEG · 2.6x EV/Rev Lower Multiple Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
-$995M ($96M Net Debt (0.09x D/E)) $50M EBITDA ($6.56 Book/Sh · -0.0% ROE) Higher Cash / Net Cash Solvency

Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)

1M Horizon PCVX +8.5 pp
PCVX: -2.51% · LEGN: -11.01%
3M Horizon PCVX +28.71 pp
PCVX: +3.73% · LEGN: -24.98%
6M Horizon PCVX +67.08 pp
PCVX: +28.03% · LEGN: -39.05%
1Y Horizon PCVX +83.13 pp
PCVX: +36.16% · LEGN: -46.97%

Financial Trajectory Operating Profitability Benchmark (Trailing 12-Month)

Split-Invariant USD Revenue & Operating Margin (%)

Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on PCVX vs LEGN. Trailing 12-month operating profitability (PCVX 0.0% vs LEGN 2.8%) and valuation multiples (PCVX N/M vs LEGN 27.5x Forward P/E) are benchmarked directly in Pillar 4 below.

PCVX ADR TTM Benchmark FX-Normalized USD
TTM RevenueN/A
Gross MarginN/A
Op. Margin0.0%
ROE / Fwd P/E-42.7% · N/M
LEGN ADR TTM Benchmark FX-Normalized USD
TTM Revenue$1.36B
Gross Margin57.0%
Op. Margin2.8%
ROE / Fwd P/E-0.0% · 27.5x

Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor

Live Options Phase Tracker
PCVX CONSOLIDATION
62d in phase · OBV NEUTRAL
Current IV 52.2%
IV Percentile 10th %ile
Put/Call OI Skew N/A
IV Regime Compressed (<25th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal BULLISH
OBV Flow NEUTRAL
Exact PCVX Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
LEGN UNCLASSIFIED
0d in phase · OBV NEUTRAL
Current IV 42.4%
IV Percentile 24th %ile
Put/Call OI Skew Thin ADR Chain
IV Regime Compressed (<25th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow NEUTRAL
Exact LEGN Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →

Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity

Corporate R&D & Foundry Leaderboard
PCVX Moat Profile Cyclical / Execution-Driven Positioning
Biotechnology Operator
Competes within the Biotechnology value chain with $10.2B market capitalization and 0.0% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published
LEGN Moat Profile Cyclical / Execution-Driven Positioning
Biotechnology Operator
Competes within the Biotechnology value chain with $3.6B market capitalization and 2.8% operating margin.
OpEx & R&D Reinvestment 54.2% of Rev ($736M)
90D Engineering Disclosures 0 Published

Investor FAQ PCVX vs LEGN Key Questions & Quantitative Answers

As of Nov 16, 2026, Legend Biotech Corporation (LEGN) is the stronger overall head-to-head candidate over Vaxcyte, Inc. (PCVX) in the Tradestie Institutional Equity Comparison Engine, winning 5–4 core matrix metrics and 5–1 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Profitability & Quality). PCVX carries a Unified Composite Score of 47.3/100 (HOLD) at $62.02 (N/M Forward P/E, 0.0% operating margin), whereas LEGN carries 42.8/100 (HOLD) at $16.45 (27.5x Forward P/E, 2.8% operating margin). Composite vs. Pillar Nuance: While PCVX currently prints a higher short-term Unified Composite Score (47.3/100 HOLD vs. LEGN 42.8/100 HOLD), LEGN captures the overall institutional head-to-head verdict (5–4 matrix metrics and 5–1 across the 6 pillars) due to superior fundamental profitability (2.8% vs. 0.0% operating margin) and revenue trajectory (+32.0% vs. +0.0% YoY). Technical & Structure Timing Caution: PCVX trades in a Neutral technical trend (CONSOLIDATION options phase, RSI 47.2); meanwhile LEGN is in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 34.5). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

LEGN leads the Growth & Scale pillar: PCVX posts +0.0% YoY revenue growth and +0.0% YoY earnings growth on N/A TTM revenue (N/A gross margin, 0.0% operating margin), compared with LEGN at +32.0% YoY revenue growth and +0.0% YoY earnings growth on $1.36B TTM revenue (57.0% gross margin, 2.8% operating margin). On trailing 12-month operating scale, PCVX generates N/A in USD-normalized revenue versus $1.36B for LEGN. In operating R&D and SG&A reinvestment, PCVX deploys N/A (0 90-day corporate R&D disclosures) versus 54.2% of Rev ($736M) (0 disclosures) for LEGN.

LEGN screens cheaper on headline valuation multiples. PCVX trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported FCF margin), whereas LEGN trades at 27.5x Forward P/E, 23.0x Trailing P/E, N/M PEG, and 2.6x EV/Revenue (3.7% EBITDA margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against PCVX (-42.7% ROE) versus LEGN (-0.0% ROE) capital efficiency.

In options market volatility and institutional positioning, PCVX carries 52.2% implied volatility (10th %ile, Compressed (<25th %ile)), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in a CONSOLIDATION options structure phase (1.28β · 57% Vol realized risk). By comparison, LEGN carries 42.4% implied volatility (24th %ile, Compressed (<25th %ile)), thin ADR options open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (0.65β · 82% Vol realized risk).

Cross-Compare 1-Click Peer Rivalries & Single-Stock Research

Launch Custom Ticker Comparison →

Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 16, 2026. For educational research only; not investment advice.